Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH
This article provides a revenue breakdown for Theravance Biopharma, Inc. (NASDAQ:TBPH). The company generated $107.46 million USD in revenue last year, primarily from its Human Therapeutics segment. The United States was the largest contributor to this revenue.
Theravance Biopharma Deal Faces Investor Probe
Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's board fulfilled its fiduciary duties. Theravance maintains that the deal offers significant value, representing a premium over its stock price before the acquisition announcement.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best price for shareholders, conduct a fair sales process, and disclose all material information. The firm encourages Theravance shareholders to contact them to discuss their rights and options.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price, conducted a fair sales process, and disclosed all material information to shareholders. Halper Sadeh LLC may seek increased consideration or other relief on behalf of investors.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC is investigating the sale of Theravance Biopharma, Inc. (TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price for shareholders, ensure a fair sales process, and disclose all material information. Halper Sadeh LLC aims to seek increased consideration or other relief for shareholders.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The firm is examining whether Theravance and its board of directors violated federal securities laws or breached their fiduciary duties by failing to secure the best possible price for shareholders, conduct a fair sales process, or disclose all material information related to the transaction. Halper Sadeh LLC represents investors globally who have been victims of securities fraud and corporate misconduct.
Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH
Wedge Capital Management L L P NC recently acquired 128,845 shares of Theravance Biopharma (NASDAQ:TBPH) worth approximately $2.19 million, now owning about 0.25% of the company. Institutional investors hold 99.10% of TBPH, despite the company reporting an adjusted loss and missing revenue expectations in its latest quarterly earnings. Analyst ratings for Theravance Biopharma are mostly "Hold," with a consensus price target of $19.40, while insiders have sold a significant number of shares recently.
Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A
Newtyn Management, LLC has disclosed a 6.7% beneficial ownership in Theravance Biopharma (TBPH) through an amended Schedule 13G filing. While Newtyn TE Partners, LP, a part of Newtyn Management, has reduced its holdings to below the 5% reporting threshold, Newtyn Management itself remains above this level. The ownership is based on 51,553,005 Ordinary Shares outstanding as of April 30, 2026.
Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake
An investor group led by Madison Avenue International LP has reported a 17.7% beneficial stake in Theravance Biopharma, Inc. (TBPH) as of June 30, 2026. This ownership, comprising 9,212,252 Ordinary Shares, is based on 51,918,754 outstanding shares as of July 31, 2026. The group, including Madison Avenue Partners, EMAI Management, Madison Avenue GP, Caraway Jackson Investments LLC, and Eli Samaha, collectively holds shared voting and dispositive power over these shares.
Theravance Biopharma (TBPH) Stock Caught Between Fading Gains And Royalty Doubts
Theravance Biopharma (TBPH) reported a significant shift from profit to loss in Q2 2026, with revenue declining by 20.9% year-over-year. The company's earnings per share also moved into negative territory, raising doubts about its reliance on lumpy royalty income and past one-off gains. Both bullish and bearish perspectives highlight the stock's struggle to transition to a steady royalty and orphan drug model, with the market reaction indicating little change in its core thesis.
Theravance Biopharma, Inc. 2026: Revenue $20.73M, EPS ($0.11) — 10-Q Summary
Theravance Biopharma, Inc. (TBPH) reported its 2026 quarterly results, showing a significant decrease in revenue and a net loss compared to the prior year. Revenue dropped by 20.9% to $20.73M, resulting in a diluted EPS of ($0.11) versus $1.08 previously, largely due to the failure of the ampreloxetine Phase 3 trial and subsequent restructuring. The company is undergoing a strategic shift with a merger agreement with Zymeworks and a significant reduction in operating expenses.
Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH
Renaissance Technologies LLC has acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH), purchasing 127,916 shares valued at approximately $2.076 million. This makes Renaissance Technologies LLC one of many institutional investors with holdings in TBPH, as they collectively own 99.10% of the company's stock. Despite the institutional interest, company insiders have sold over 350,000 shares worth $6.0 million in the past quarter, and analysts generally rate the stock as a "Hold" with a consensus price target of $19.40.
Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. (TBPH) reported its second quarter 2026 financial results, highlighting a significant 15% increase in total revenue year-over-year, reaching $40 million. The company's net loss decreased by 10% to $18 million, or $0.30 per share, demonstrating improved financial performance. Key updates included advancements in its pipeline, particularly with izokibep, and a reiteration of its full-year 2026 financial guidance.
Theravance Biopharma Releases Q2 2026 Financial Results
Theravance Biopharma, Inc. (TBPH) reported mixed financial results for Q2 2026, with non-GAAP EPS of $0.11 and revenue of $20.7 million, down 20.9% year-over-year. Despite the revenue decline, the company achieved profitability with a net income of $9.5 million. The revenue was primarily driven by its key product, YUPELRI, which generated $20.7 million, an 11.0% increase from the previous year.
Theravance Biopharma Releases Q2 2026 Financial Results
Theravance Biopharma (TBPH) reported mixed financial results for Q2 2026, with non-GAAP earnings per share of $0.11 and a net income of $9.5M, despite a 20.9% decline in revenue to $20.7M year-over-year. The company's key product, YUPELRI, generated $20.7M in revenue, showing 11.0% year-over-year growth. Wall Street analysts hold diverse views, with consensus at 4 buy and 5 hold ratings for the biopharmaceutical company.
Form 8K Theravance Biopharma Inc For: 10 August By Investing.com
This article reports on the filing of a Form 8K by Theravance Biopharma Inc. for August 10. The short piece from Investing.com provides no further details beyond the title and company information.
Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY
Theravance Biopharma reported a Q2 GAAP net loss of USD 5.9 million, a swing from a profit in the prior year, despite an 11% increase in revenue to USD 20.7 million, primarily from the Viatris collaboration. The company also saw reduced R&D and SG&A expenses, though it incurred transaction-related costs for the Zymeworks acquisition and restructuring expenses. The acquisition by Zymeworks for USD 17 per share plus a CVR is expected to close in the second half of 2026.
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings per share of $0.07, matching analysts' consensus estimates. The company showed a strong return on equity of 18.84% and a net margin of 104.34%. Analysts currently maintain a "Hold" rating on the stock with a consensus price target of $19.40, while insider selling activity and institutional ownership details were also highlighted.
Is Theravance Biopharma Inc (TBPH) Undervalued After Q2 Earnings
Theravance Biopharma Inc (TBPH) released its Q2 2026 earnings, reporting an 11% increase in YUPELRI collaboration revenue to $20.7 million and a 35% reduction in operating expenses. Despite these gains and a solid cash balance, the company faces challenges, including a failed Phase 3 clinical study for ampreloxetine and uncertainties surrounding its acquisition by Zymeworks. GuruFocus values TBPH as undervalued at $24.1 compared to its current price of $16.93, suggesting an attractive entry point for value investors, though caution is advised due to insider selling and low predictability.
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q2 Revenue $20.7M, vs. FactSet Est of $22.5M
Theravance Biopharma, Inc. (TBPH) announced its Q2 revenue of $20.7 million, falling short of FactSet's estimate of $22.5 million. The company's stock was trading at 16.90 USD, reflecting a slight dip in performance. Theravance Biopharma specializes in developing and commercializing medicines for respiratory and neurologic diseases, with key products like YUPELRI for COPD and Ampreloxetine in development for neurogenic orthostatic hypotension.
Form 8K Theravance Biopharma Inc For: 10 August By Investing.com
This article announces that Theravance Biopharma Inc. filed a Form 8K on August 10, 2026. The filing is a standard SEC disclosure for significant corporate events. The brief note from Investing.com provides no further details about the content of the 8K.
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. announced its Q2 2026 financial results, highlighted by an 11% year-over-year increase in YUPELRI collaboration revenue and a significant 35% reduction in operating expenses due to restructuring. The company also confirmed its pending acquisition by Zymeworks for $17.00 per share cash plus a CVR, expected to close in the second half of 2026. Theravance Biopharma remains confident in achieving a $100 million milestone payment from Royalty Pharma based on TRELEGY net sales.
Theravance Bio: Q2 Earnings Snapshot
Theravance Biopharma Inc. (TBPH) reported a second-quarter loss of $5.9 million, or 11 cents per share. Adjusted earnings were 19 cents per share, while the company's revenue of $20.7 million surpassed analyst expectations of $19.8 million. This financial snapshot highlights their performance in the recent quarter.
TBPH: Zymeworks Cash Deal And CVR Will Shape Post Ampreloxetine Path
Theravance Biopharma's fair value has increased to $17.67, aligning closely with Zymeworks' $17 per share cash acquisition offer. Analysts are focusing on the implications of the deal, with bullish views highlighting the clear valuation anchor and durable cash flow, while bearish sentiments emphasize that most deal value is already reflected and future upside is limited to smooth transaction execution. The acquisition also includes a contingent value right for Theravance shareholders related to future monetization of ampreloxetine.
(TBPH) Movement as an Input in Quant Signal Sets
Theravance Biopharma Inc. (NASDAQ: TBPH) is showing neutral near and mid-term readings with a potential long-term positive bias, according to Stock Traders Daily's quantitative analysis. The report highlights a significant 45.6:1 risk-reward short setup and provides specific entry, target, and stop-loss zones for various trading strategies, including position, momentum breakout, and risk hedging. AI-generated signals indicate neutral sentiment in the near and mid-term, but strong positive signals for the long term.
Theravance Biopharma Inc (TBPH) Financial Health: Profitability & Balance Sheet Analysis
Theravance Biopharma Inc (TBPH) has a strong financial score of 7.72, placing it robustly within the Pharmaceuticals industry. The company reported a significant 15.02% year-over-year increase in quarterly revenue, reaching $17.70M, and its net profit surged by 63.67% year-over-year. This analysis highlights TBPH's robust financial status and high operating efficiency, despite some relevant data not yet being disclosed.
ETFs Investing in Theravance Biopharma Inc Stocks
This article lists various Exchange Traded Funds (ETFs) that hold shares of Theravance Biopharma Inc. Each ETF entry includes details such as market value, weight of Theravance Biopharma stock in the fund, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies including biotechnology, small cap, micro cap, and health care.
TBPH|Theravance Biopharma Inc|Price:16.865|Chg%:+0.005
This article provides a comprehensive stock analysis of Theravance Biopharma Inc (TBPH) using the TradingKey Stock Score. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. While institutional ownership is high, analysts have rated it as "Hold" with a stable short-term price outlook.
Theravance Biopharma Inc (TBPH) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an in-depth analysis of Theravance Biopharma Inc's (TBPH) shareholder structure, detailing major individual and institutional holdings. It breaks down shareholders by type and lists the changes in institutional shareholding over recent quarters, alongside related ETF holdings. Key data includes top shareholders like Madison Avenue Partners LP and Weiss Asset Management, and the percentage held by different investor types.
Theravance Biopharma Inc Revenue Breakdown – FWB:0TB
Theravance Biopharma Inc. (FWB: 0TB) generated €91.50 million in revenue last year, primarily from its Human Therapeutics segment. This marks an increase from the previous year's €62.19 million, with the United States being the largest contributor to revenue.
Theravance Biopharma Inc Revenue Breakdown – LS:A1137V
Theravance Biopharma Inc (A1137V) generated 91.50 million EUR in revenue last year, primarily from its Human Therapeutics segment. The United States was the largest contributor to this revenue, accounting for 63.83 million EUR. This represents an increase from the previous year's total revenue of 62.19 million EUR.
Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co.
HC Wainwright & Co. has increased its price target for Theravance Biopharma (TBPH) shares to $17.00, up from the previous target of $15.00. This adjustment reflects an updated outlook on the company's valuation.
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future
Zymeworks is strategically pivoting beyond its oncology focus with the $929 million acquisition of Theravance Biopharma, gaining the FDA-approved COPD therapy, Yupelri. This move aligns with current biopharma M&A trends emphasizing de-risked, cash-generating assets to address patent cliffs. While Yupelri offers stable revenue and long-term intellectual property, Zymeworks faces the challenge of integrating a respiratory asset into its existing clinical-stage oncology pipeline.
TBPH - Theravance Biopharma Inc Options
This article provides a detailed financial overview of Theravance Biopharma Inc. (TBPH), including its latest stock performance, market capitalization, key financial ratios, and insider/institutional ownership data. It presents various metrics such as P/E, sales growth, profit margins, and volatility, along with analyst recommendations and target prices. The data aims to give investors a comprehensive snapshot of the company's current financial health and market position.
TBPH SEC Filings - Theravance Bioph 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Theravance Biopharma (TBPH) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. Recent filings detail equity grants to executives, a patent settlement for YUPELRI® extending generic availability to 2039, and the company's strategic restructuring and evaluation of alternatives following the ampreloxetine program wind-down, aiming to significantly reduce operating expenses. The detailed entries offer AI-generated summaries, impact scoring, and sentiment analysis for each filing.
TBPH - Theravance Biopharma Inc Short Interest
This article provides a detailed overview of Theravance Biopharma Inc (TBPH) stock, focusing on various financial metrics, short interest data, and performance indicators. It includes information on the company's market capitalization, income, sales, P/E ratio, short interest percentage, and analyst recommendations. The data presented covers fundamental, technical, and performance aspects of the stock.
TBPH - Theravance Biopharma Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for Theravance Biopharma Inc (TBPH), including its latest stock close, market capitalization, income, sales, and various financial ratios. It also outlines insider ownership, institutional ownership, and short interest, along with price performance over different periods and analyst recommendations.
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Theravance Biopharma has announced a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash, totaling approximately $929 million in equity value. In addition to the cash payment, Theravance Biopharma shareholders will receive a contingent value right (CVR) for 80% of net proceeds from any future monetization of ampreloxetine over the next ten years. This transaction, which is subject to shareholder and regulatory approvals, is expected to close in the second half of 2026 and follows a comprehensive strategic review by the company's board.
Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales
Funds associated with Eli Samaha, managed by Madison Avenue Partners, LP, have significantly reduced their stake in Theravance Biopharma (TBPH) through open-market sales. Over three days, the funds sold a total of 336,697 shares at weighted average prices around $17 per share. Despite these sales, Madison Avenue Partners, LP entities still indirectly hold a substantial 9,174,453 shares of Theravance Biopharma common stock.
Zymeworks to acquire Theravance Biopharma in deal worth $929m
Zymeworks has announced its acquisition of Theravance Biopharma in a deal valued at approximately $929 million. This strategic move grants Zymeworks ownership of Yupelri, a key treatment for Chronic Obstructive Pulmonary Disease (COPD), broadening its portfolio. The acquisition aligns with Zymeworks' goal of diversifying its business through a combination of partner-driven cash flows and innovative R&D.
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks
Arthur Cox advised Theravance Biopharma, Inc. on its definitive agreement to be acquired by Zymeworks Inc. for approximately US$929 million. The transaction values Theravance Biopharma at US$17.00 per share, plus a contingent value right for future proceeds from ampreloxetine. This acquisition, which follows a strategic review, is expected to close in the second half of 2026.
Zymeworks agrees to buy Theravance Biopharma for $929m
Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma for approximately $929 million (C$1.32bn). Theravance Biopharma shareholders will receive $17 per share plus a contingent value right for 80% of net proceeds from future monetization of ampreloxetine. The deal, unanimously approved by both boards, is expected to close in the second half of 2026, pending shareholder and regulatory approvals.
Canadian Zymeworks acquires American Theravance Biopharma for $929 million
Canadian biotech company Zymeworks Inc. has agreed to acquire American Theravance Biopharma Inc. for $929 million, with the transaction expected to close in the second half of 2026. This acquisition supports Zymeworks' strategy to diversify its portfolio and optimize product value, including profiting from the sale of the Yupelri drug for chronic lung disease and acquiring Theravance's research and development assets.
Theravance Stock Down 3% After Zymeworks Announces Buyout
Theravance Biopharma's stock dropped 3% after announcing an all-cash acquisition by Zymeworks Inc. for approximately $929 million. The deal follows a strategic review by Theravance after its lead candidate, ampreloxetine, failed in a pivotal phase III study. Shareholders will receive $17.00 per share plus a contingent value right for 80% of future net proceeds from ampreloxetine's monetization.
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion
Zymeworks is set to acquire Theravance Biopharma in a complex deal valued at less than $1 billion, marking the end of Theravance's three-decade legacy. Despite the sale, Theravance CEO Rick Winningham expressed ongoing commitment to creating impactful medicines. The acquisition highlights the dynamic and challenging nature of the biotechnology industry.
Zymeworks agrees to buy Theravance Biopharma for $929m
Canadian biotechnology company Zymeworks has reached an agreement to acquire Theravance Biopharma for approximately $929m in cash. Theravance Biopharma shareholders will receive $17 per share plus a contingent value right for 80% of future net proceeds from ampreloxetine, a drug for multiple system atrophy. The transaction is expected to close in the second half of 2026, pending shareholder and regulatory approvals.
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc.
This press release announces Zymeworks' intent to acquire Theravance Biopharma, Inc. The acquisition is expected to create a stronger combined entity with an enhanced pipeline and capabilities. Further details about the terms of the acquisition and strategic rationale are anticipated in the full document.
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
This article details two significant pharmaceutical acquisitions: Zymeworks' agreement to acquire Theravance Biopharma for approximately $929 million, primarily for its commercial COPD asset Yupelri and Irish tax attributes, and Ipsen's plan to acquire Kartos Therapeutics for up to $1.75 billion, adding the investigational MDM2 inhibitor navtemadlin to its oncology pipeline. Both deals aim to strengthen the acquirers' commercial portfolios and R&D pipelines, with Zymeworks focusing on profitability and Ipsen on late-stage oncology assets.
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks announced it will acquire Theravance Biopharma for $929 million in an all-cash transaction, expected to close in the second half of 2026. This acquisition will add Yupelri, a COPD treatment, to Zymeworks' commercial portfolio, giving it a 35% share of U.S. net profits from the drug. Zymeworks plans to finance the deal through a $350 million note, existing cash, and Theravance’s net cash balance, while also continuing its share repurchase program.
Zymeworks makes bold move with $929m Theravance Biopharma buy
Zymeworks has announced a $929 million acquisition of Theravance Biopharma, marking its entry into the respiratory disease sector. The deal centers on Yupelri, an FDA-approved COPD therapy, and is financed through a non-recourse arrangement, including a $350 million note and Theravance's cash balance. This strategic move aims to diversify Zymeworks' revenue, strengthen its financial position, and fund its oncology pipeline.
